Stay updated on Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial page.

Latest updates to the Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check21 days agoChange DetectedThe webpage has undergone significant changes, including the removal of detailed information about a phase II clinical trial for urothelial cancer, while adding new identifiers and collaborators related to the study.SummaryDifference48%
- Check28 days agoNo Change Detected
- Check36 days agoNo Change Detected
- Check79 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check86 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check93 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check108 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
Stay in the know with updates to Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial page.